Extrapleural Pneumonectomy for Malignant Mesothelioma: An Italian Multicenter Retrospective Study

Spaggiari, Lorenzo; Marulli, Giuseppe; Bovolato, P; Alloisio, Marco; Pagan, V.; Oliaro, A; Ratto, G. B.; Facciolo, Francesco; Sacco, Rodolfo; Brambilla, Daniela; Maisonneuve, Patrick; Mucilli, Felice; Alessandrini, Gabriele; Leoncini, Giacomo; Ruffini, Enrico; Fontana, Paolo; Infante, Maurizio; Pariscenti, Gian Luca; Casiraghi, Monica; Rea, Federico

doi:10.1016/j.athoracsur.2014.01.050

Cited by 43 publications

(42 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LTS was defined as survival longer than two times the median overall survival (OS; 18 months) reported in our previous study [10]. Patients were stratified into two groups according to LTS: patients surviving at least 36 months (LTS group) and those surviving between 4 and 35 months (short-term survival [STS] group) after EPP.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Score of Long-Term Survival After Surgery for Malignant Pleural Mesothelioma: A Multicenter Analysis

Leuzzi¹,

Rea

Spaggiari

et al. 2015

The Annals of Thoracic Surgery

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Score of Long-Term Survival After Surgery for Malignant Pleural Mesothelioma: A Multicenter Analysis

Leuzzi¹,

Rea

Spaggiari

et al. 2015

The Annals of Thoracic Surgery

Self Cite

View full text Add to dashboard Cite

show abstract

“…Another recent study in a general MPM population found that 24% of patients survived more than 20 months, but only 66 and 16% of them had received CT and EPP, respectively [3]. Overall, the percentage of patients surviving more than 3 years was about 10-15% in populationbased studies, growing to 18-68% in patients who underwent surgery [5,20,26,27].…”

Section: Discussionmentioning

confidence: 96%

“…The benefit of EPP has been questioned, and reanalysis of a large number of studies showed that P/D is associated with a 2.5-fold lower perioperative and short-term (30 days) mortality than EPP [22,23]. The advantage increases in patients with favorable prognostic predictors when treated with surgery combined with CT and postoperative radiotherapy [20,24].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma

Filiberti

Taveggia²,

Grosso

et al. 2017

Oncol Res Treat

View full text Add to dashboard Cite

Background: Malignant pleural mesothelioma is a problematic condition due to poor prognosis and difficulties in management. We evaluated the treatment and outcome of 378 mesothelioma patients referred to 6 Italian Oncology Departments. Methods: Demographic and clinical data were collected. Treatment was assessed in terms of chemotherapy (line of treatment, pemetrexed-based regimen, other therapies), surgery, and radiotherapy. Response to therapy, progression-free survival, and overall survival were evaluated. Results: 36 and 342 patients received best supportive care and active treatment, respectively; 86 patients underwent surgery, and 26 received trimodal therapy. Disease control after first-line chemotherapy was achieved in 74.2% of patients (75.7% in patients treated with pemetrexed combined with other drugs and 69% with pemetrexed as monotherapy). The disease control rate was 82.6% in pemetrexed re-challenged individuals. Median survival time was 11.6 months with supportive care, 16.2 months with chemotherapy only, 32.4 months with surgery plus chemotherapy, and 47.2 months with trimodal therapy. A more favorable prognosis was observed in responders to first-line therapy who were then actively treated with second-line (24.8 vs. 11.8 months in non-responders, p < 0.001) and third-line chemotherapy (28.9 vs. 17.8 months in non-responders, p = 0.005). Conclusion: Mesothelioma patients benefited from chemotherapy alone only when retreated in the second line after response to first-line therapy.

show abstract

“…On the one hand EPP seems to be more radical than P/D (13,14), on the other hand P/D appears to have lower mortality and morbidity rate (15,16). Because of the absence of randomized trials comparing long term survival and results of P/D and EPP, which is the best surgical procedure remains clouded.…”

Section: Discussionmentioning

confidence: 99%

Surgery for malignant pleural mesothelioma: an international guidelines review

Ricciardi¹,

Cardillo²,

Zirafa³

et al. 2018

J. Thorac. Dis.

Self Cite

View full text Add to dashboard Cite

Currently there is no universally accepted surgical therapy for malignant pleural mesothelioma (MPM). The goal of surgery in this dismal disease is a macroscopic complete resection (MCR) and there are two types of intervention with a curative intent. At one side, there is the extrapleural pneumonectomy (EPP) which consists in an en-bloc resection of the lung, pleura, pericardium and diaphragm and at the other side, there is pleurectomy/decortication (P/D) a lung-sparing surgery. Initially, EPP was considered the only surgical option with a curative aim, but during the decades P/D have acquired a role of increasing importance in MPM therapy. Several randomized prospective trials are required to establish the best strategy in the treatment of pleural mesothelioma. Although which is the best surgical option remains unclear, the International Mesothelioma Interest Group (IMIG), recently have stated that the type of surgery depends on clinical factors and on individual surgical judgment and expertise. Moreover, according to the current evidence, the surgery should be performed in high-volume centres within multimodality protocols. The aim of this study is to examine the currently available international guidelines in the surgical diagnosis and treatment of MPM.

show abstract

Extrapleural Pneumonectomy for Malignant Mesothelioma: An Italian Multicenter Retrospective Study

Cited by 43 publications

References 20 publications

Prognostic Score of Long-Term Survival After Surgery for Malignant Pleural Mesothelioma: A Multicenter Analysis

Prognostic Score of Long-Term Survival After Surgery for Malignant Pleural Mesothelioma: A Multicenter Analysis

Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma

Surgery for malignant pleural mesothelioma: an international guidelines review

Contact Info

Product

Resources

About